Norwegian pharmaceutical company Pronova BioPharma, which in September 2007 broke ground for a new DKK 1.5bn (USD 270m) factory in the Danish port town of Kalundborg, expects the plant to be in commercial operation in a year's time, reports Erhvervsbladet.
The company, which manufactures marine-originated omega-3* derived pharmaceutical products, has already recruited 90 staff who are being trained at Pronova BioPharma's Norwegian facility. The new plant in Denmark will enable the company to double its current production from 1,200 tons to 2,400 tons.
The company's first commercialised omega-3 derived prescription product Omacor (Lovaza in US) is a dietary adjunct for the treatment of elevated triglycerides, which are widely regarded as a risk factor for cardiovascular disease, especially in the overweight.
The siting of Pronova BioPharma's factory in the same area of the country as Novo Nordisk, Novozymes, and their network of sub-suppliers, has benefited recruitment. Kjetil Olsen, managing director of Pronova BioPharma in Denmark, told Erhvervsbladet: "There is a clear advantage in locating ourselves in a cluster region with several thousand people employed in pharmaceutical production."
Erhvervsbladet reports that there is a strong demand for Pronova BioPharma's products in the US, where obesity is a common problem. In the first 9 months of 2008 Pronova BioPharma manufactured 893 tons of products compared with 653 tons in 2007, an increase of 36%.
Pronova BioPharma's omega-3 products are produced from fish oil from anchovies and sardines caught in the Pacific and Atlantic Oceans.
*omega-3 fatty acids, commonly found in fish oil and vegetable oil, are so-named because they have a final unsaturated bond at the third carbon atom from the omega end (meaning "tail end") of the molecule – Ed.